Sorafenib: Where do we go from here? Review uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Benzenesulfonates
  • Carcinoma, Hepatocellular
  • Intracellular Signaling Peptides and Proteins
  • Liver Neoplasms
  • Protein Kinase Inhibitors
  • Protein-Serine-Threonine Kinases
  • Pyridines
  • Receptors, Vascular Endothelial Growth Factor

abstract

  • The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely multidisciplinary way requiring surgeons, hepatologists, interventional radiologists, and oncologists. This review describes the molecular pathogenesis of HCC, explores current and future treatments based on these pathways, and describes how these new therapies may augment existing approaches to HCC treatment.

publication date

  • July 2010

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3605708

Digital Object Identifier (DOI)

  • 10.1002/hep.23633

PubMed ID

  • 20578152

Additional Document Info

start page

  • 360

end page

  • 9

volume

  • 52

number

  • 1